

Vito Di Marco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/668524/publications.pdf>

Version: 2024-02-01

169
papers

8,600
citations

34105
52
h-index

49909
87
g-index

170
all docs

170
docs citations

170
times ranked

9168
citing authors

#	ARTICLE	IF	CITATIONS
1	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , 2015, 61, 506-514.	7.3	424
2	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	13.7	345
3	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018, 155, 411-421.e4.	1.3	291
4	Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. <i>Hepatology</i> , 2004, 40, 883-891.	7.3	237
5	The long-term course of chronic hepatitis B. <i>Hepatology</i> , 1999, 30, 257-264.	7.3	199
6	Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007, 39, 397-408.	0.9	197
7	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 62, 1101-1110.	7.3	183
8	Comparison of Transient Elastography and Acoustic Radiation Force Impulse for Non-Invasive Staging of Liver Fibrosis in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2011, 106, 2112-2120.	0.4	177
9	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	7.3	177
10	Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006, 43, 64-71.	7.3	163
11	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. <i>Journal of Hepatology</i> , 2015, 62, 928-933.	3.7	162
12	SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009, 49, 1821-1827.	7.3	151
13	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1604-1611.e1.	4.4	146
14	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273.	3.7	138
15	Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <sc>NAFLD</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	3.7	134
16	Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. <i>Gastroenterology</i> , 2016, 151, 130-139.e2.	1.3	130
17	Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1350-1360.	3.7	126
18	Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 757-766.	3.7	125

#	ARTICLE	IF	CITATIONS
19	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 688-695.	3.7	124
20	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015, 35, 1566-1573.	3.9	116
21	Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. <i>Hepatology</i> , 2012, 55, 1317-1323.	7.3	113
22	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885.	3.7	113
23	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87523.	2.5	112
24	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1202-1216.	3.7	111
25	Risk Factors and Outcome among a Large Patient Cohort with Community-Acquired Acute Hepatitis C in Italy. <i>Clinical Infectious Diseases</i> , 2006, 43, 1154-1159.	5.8	108
26	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 682-690.	3.7	106
27	Randomised study comparing 48 and 96 weeks peginterferon α -2a therapy in genotype D HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2013, 62, 290-298.	12.1	105
28	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 935-944.e3.	4.4	102
29	Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. <i>Journal of Hepatology</i> , 2005, 42, 535-540.	3.7	101
30	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018, 69, 18-24.	3.7	98
31	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 850-860.	7.3	97
32	Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 238-247.	3.7	97
33	Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial. <i>Journal of Hepatology</i> , 2007, 47, 484-491.	3.7	96
34	Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. <i>Hepatology</i> , 2010, 52, 1543-1552.	7.3	95
35	Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. <i>Hepatology</i> , 1994, 19, 820-8.	7.3	94
36	Peginterferon α -2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. <i>Journal of Hepatology</i> , 2004, 41, 474-481.	3.7	91

#	ARTICLE	IF	CITATIONS
37	Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. Journal of Viral Hepatitis, 2013, 20, 867-874.	2.0	91
38	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood, 2010, 116, 2875-2883.	1.4	79
39	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis, 2020, 296, 40-47.	0.8	78
40	Long-term course of interferon-treated chronic hepatitis C. Journal of Hepatology, 1998, 28, 531-537.	3.7	77
41	Interferon lambda 4 rs368234815 TT>ÎG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology, 2017, 66, 1885-1893.	7.3	75
42	Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. Liver International, 2018, 38, 2060-2068.	3.9	72
43	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. Journal of Hepatology, 2014, 61, 523-529.	3.7	67
44	Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. Hepatology, 2017, 66, 736-745.	7.3	67
45	Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World Journal of Hepatology, 2012, 4, 256.	2.0	67
46	The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2007, 25, 1181-1191.	3.7	66
47	Anti-Tissue Transglutaminase Antibodies in Patients with Abnormal Liver Tests: Is It Always Coeliac Disease?. American Journal of Gastroenterology, 2005, 100, 2472-2477.	0.4	65
48	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology, 2009, 49, 195-203.	7.3	65
49	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2013, 8, e74089.	2.5	59
50	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. Diabetes, Obesity and Metabolism, 2020, 22, 2408-2416.	4.4	58
51	Retinol-binding protein 4: A new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. Hepatology, 2008, 48, 28-37.	7.3	55
52	Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Antiviral Therapy, 2009, 14, 649-654.	1.0	53
53	Combined treatment of relapse of chronic hepatitis C with high-dose Î±2b interferon plus ribavirin for 6 or 12 months. Journal of Hepatology, 2000, 33, 456-462.	3.7	51
54	Oral pathology in untreated coeliac disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 1529-1536.	3.7	50

#	ARTICLE	IF	CITATIONS
55	Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. <i>Haematologica</i> , 2008, 93, 1243-1246.	3.5	50
56	Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 196-204.	3.7	50
57	Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) – lack of interference by iron deposition. <i>British Journal of Haematology</i> , 2010, 148, 476-479.	2.5	49
58	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 310-317.	0.9	47
59	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. <i>Haematologica</i> , 2012, 97, 679-686.	3.5	46
60	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2660-2669.	3.6	42
61	Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. <i>American Journal of Hematology</i> , 2017, 92, 1349-1355.	4.1	42
62	Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 92-104.	3.7	41
63	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2345-2353.	2.6	40
64	HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. <i>Journal of Hepatology</i> , 2004, 40, 831-836.	3.7	39
65	Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. <i>Journal of Hepatology</i> , 2004, 40, 478-483.	3.7	38
66	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	3.7	38
67	HCV viraemia is more important than genotype as a predictor of response to interferon in sicily (Southern Italy). <i>Journal of Hepatology</i> , 1996, 25, 583-590.	3.7	37
68	Hepatocellular Carcinoma Presenting at Contrast-Enhanced Multi-Detector-Row Computed Tomography or Gadolinium-Enhanced Magnetic Resonance Imaging as a Small (<2 cm), Indeterminate Nodule. <i>Journal of Computer Assisted Tomography</i> , 2012, 36, 20-25.	0.9	34
69	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , 2017, 37, 1526-1534.	3.9	34
70	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013, 59, 1169-1176.	3.7	33
71	Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients. <i>Journal of Medical Virology</i> , 2003, 70, 581-587.	5.0	32
72	Hyperferritinemia is a risk factor for steatosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2132.	3.3	32

#	ARTICLE	IF	CITATIONS
73	Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. <i>Digestive and Liver Disease</i> , 2010, 42, 585-592.	0.9	30
74	HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 312-321.	4.4	30
75	Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: A prospective study. <i>Digestive and Liver Disease</i> , 2008, 40, 684-689.	0.9	29
76	Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011, 43, 259-265.	0.9	29
77	Vitamin D Levels and IL28B Polymorphisms are Related to Rapid Virological Response to Standard of Care in Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2012, 17, 823-831.	1.0	29
78	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years. <i>Journal of Hepatology</i> , 2012, 56, 1254-1258.	3.7	29
79	Serum γ -glutamyl Transferase Levels, Insulin Resistance and Liver Fibrosis in Patients with Chronic Liver Diseases. <i>PLoS ONE</i> , 2012, 7, e51165.	2.5	29
80	Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response. <i>PLoS ONE</i> , 2013, 8, e70016.	2.5	29
81	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84.	7.7	29
82	Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. <i>Journal of Hepatology</i> , 1991, 12, 64-69.	3.7	28
83	Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. <i>Journal of Viral Hepatitis</i> , 2009, 17, 469-74.	2.0	28
84	Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Na ⁺ ve Patients With Primary Biliary Cholangitis: A Dual Cut-off Approach. <i>Hepatology</i> , 2021, 74, 1496-1508.	7.3	28
85	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2011, 43, 404-410.	0.9	27
86	Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , 2002, 51, 864-869.	12.1	26
87	High efficacy of direct-acting antiviral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1705-1712.	3.7	26
88	Identification of na ⁺ ve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , 2014, 60, 16-21.	3.7	25
89	Survival and causes of death in 2,033 patients with non-transfusion-dependent β -thalassemia. <i>Haematologica</i> , 2021, 106, 2489-2492.	3.5	25
90	Transfusion-associated chronic hepatitis C: Alpha-n1 interferon for 6 vs. 12 months. <i>Journal of Hepatology</i> , 1996, 24, 539-546.	3.7	24

#	ARTICLE	IF	CITATIONS
91	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Digestive and Liver Disease, 2011, 43, 875-80.	0.9	23
92	Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. Digestive and Liver Disease, 2005, 37, 882-885.	0.9	22
93	Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. Alimentary Pharmacology and Therapeutics, 2009, 30, 603-613.	3.7	22
94	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. Analytical Cellular Pathology, 2015, 2015, 1-7.	1.4	22
95	A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. , 1997, 51, 17-24.		21
96	Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?. Liver International, 2009, 29, 1171-1177.	3.9	21
97	Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. Journal of Viral Hepatitis, 2008, 15, 523-530.	2.0	20
98	TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. Journal of Viral Hepatitis, 2011, 18, e372-80.	2.0	20
99	Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. Alimentary Pharmacology and Therapeutics, 2015, 41, 477-486.	3.7	20
100	Targeted Therapies in Hepatocellular Carcinoma. Current Medicinal Chemistry, 2014, 21, 966-974.	2.4	19
101	Risk of mortality from anemia and iron overload in nontransfusionâ€dependent Î²â€thalassemia. American Journal of Hematology, 2022, 97, .	4.1	19
102	<sc>PNPLA</sc> rs738409 I748M is associated with steatohepatitis in 434 nonâ€obese subjects with hepatitis C. Alimentary Pharmacology and Therapeutics, 2015, 41, 939-948.	3.7	18
103	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. Liver International, 2020, 40, 2820-2827.	3.9	17
104	Detection of hepatitis delta virus RNA in chronic liver disease. Journal of Hepatology, 1989, 9, 23-28.	3.7	16
105	Long-term evolution of chronic delta hepatitis in children. Journal of Pediatrics, 1993, 122, 736-738.	1.8	16
106	Alpha interferon treatment of chronic hepatitis C in beta-thalassaemia.. Gut, 1993, 34, S142-S143.	12.1	16
107	Role of ILâ€28B and inosine triphosphatase polymorphisms in efficacy and safety of Pegâ€interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. Journal of Viral Hepatitis, 2013, 20, 113-121.	2.0	16
108	Oral mucosa of coeliac disease patients produces antiendomysial and antitransglutaminase antibodies: the diagnostic usefulness of an <i>in vitro</i> culture system. Alimentary Pharmacology and Therapeutics, 2007, 25, 1471-1477.	3.7	15

#	ARTICLE	IF	CITATIONS
109	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 174-182.	2.0	15
110	rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016, 36, 198-204.	3.9	15
111	Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1013-1019.	2.3	14
112	Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. <i>Journal of Viral Hepatitis</i> , 2002, 9, 354-359.	2.0	14
113	Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy. <i>Digestive and Liver Disease</i> , 2011, 43, 996-1000.	0.9	14
114	Hepatitis C: Standard of Treatment and What to Do for Global Elimination. <i>Viruses</i> , 2022, 14, 505.	3.3	14
115	Parvovirus B19 and "cryptogenic" chronic hepatitis. <i>Journal of Hepatology</i> , 2003, 38, 375-376.	3.7	13
116	Current practice of chronic hepatitis B treatment in Southern Italy. <i>European Journal of Internal Medicine</i> , 2012, 23, e124-e127.	2.2	13
117	Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 878-884.e1.	4.4	13
118	NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. <i>Cells</i> , 2019, 8, 666.	4.1	13
119	Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. <i>Digestive and Liver Disease</i> , 2019, 51, 915-921.	0.9	13
120	Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 465-472.	2.0	12
121	Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance. <i>Hepatitis Monthly</i> , 2013, 13, e7176.	0.2	12
122	Who is more likely to respond to dual treatment with pegylated interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , 2013, 20, 790-800.	2.0	11
123	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. <i>Digestive and Liver Disease</i> , 2016, 48, 650-655.	0.9	11
124	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1190-1199.	2.0	11
125	Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography. <i>Ultrasonography</i> , 2021, 40, 407-416.	2.3	11
126	Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. <i>Kidney International</i> , 2006, 70, 1187-1188.	5.2	10

#	ARTICLE	IF	CITATIONS
127	Perception of the Role of Food and Dietary Modifications in Patients with Inflammatory Bowel Disease: Impact on Lifestyle. <i>Nutrients</i> , 2021, 13, 759.	4.1	10
128	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1979-1981.	4.4	10
129	Chronic hepatitis B: who to treat and which choice of treatment?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 281-291.	4.4	9
130	Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. <i>Gut</i> , 2011, 60, 1023-1023.	12.1	9
131	HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. <i>Hepatology International</i> , 2015, 9, 52-57.	4.2	9
132	Effectiveness of a screening program for HBV, HCV, and HIV infections in African migrants to Sicily. <i>Digestive and Liver Disease</i> , 2022, 54, 800-804.	0.9	9
133	Phylogenetic analysis of isolates from new cases of HBV infection in Southern Italy. <i>Infection, Genetics and Evolution</i> , 2012, 12, 1591-1596.	2.3	8
134	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 818-825.	0.9	8
135	Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. <i>Pathobiology</i> , 2015, 82, 48-52.	3.8	8
136	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	4.4	8
137	Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence. <i>Annals of Hepatology</i> , 2021, , 100568.	1.5	8
138	Treatment with interferon alfa-2b of chronic HDV hepatitis in children. <i>Journal of Hepatology</i> , 1990, 11, S175.	3.7	7
139	High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 953-958.	3.7	7
140	Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay. <i>Journal of Viral Hepatitis</i> , 2007, 15, 070901052026012-???	2.0	7
141	A complication risk score to evaluate clinical severity of thalassaemia syndromes. <i>British Journal of Haematology</i> , 2021, 192, 626-633.	2.5	7
142	Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis. <i>Journal of Oral Pathology and Medicine</i> , 2009, 38, 34-41.	2.7	6
143	Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FIS (HEpatitis C Virus Fingerstick) Tj ETQq1.1 0.784314 rgBT /D	3.9	6
144	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , 2021, 53, 1301-1307.	0.9	6

#	ARTICLE	IF	CITATIONS
145	Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2389-2396.	2.8	6
146	rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2712-2719.	3.9	6
147	A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 1032-1044.	4.3	6
148	Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?. <i>Digestive and Liver Disease</i> , 2002, 34, 53-58.	0.9	5
149	Congenital Hepatic Fibrosis. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 567-568.	0.6	5
150	HCV Clearance Among Hemophiliacs and Beta-Thalassemics. <i>Gastroenterology</i> , 2007, 132, 1634.	1.3	5
151	Chronic hepatitis C in children is a mild and curable liver disease. <i>Digestive and Liver Disease</i> , 2011, 43, 266-267.	0.9	5
152	Impact of HBV genotypes A and D genetic variability on infection evolution. <i>Infection, Genetics and Evolution</i> , 2015, 33, 281-287.	2.3	5
153	Factors Enhancing Treatment of Hepatitis C Virusâ€“Infected Italian People Who Use Drugs: The CLEO-GRECA Experience. <i>American Journal of Gastroenterology</i> , 2021, 116, 1248-1255.	0.4	5
154	HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors. <i>Infection, Genetics and Evolution</i> , 2014, 23, 80-85.	2.3	4
155	Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. <i>Infection</i> , 2019, 47, 409-415.	4.7	4
156	Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy. <i>Journal of Hospital Infection</i> , 2021, 115, 51-58.	2.9	4
157	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	3.9	4
158	Adefovir for lamivudine resistant HBV: More than meets the eye. <i>Journal of Hepatology</i> , 2007, 47, 618-619.	3.7	3
159	Long-term evolution of LIâ€“RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. <i>Liver International</i> , 2021, 41, 2179-2188.	3.9	3
160	Random Forest Clustering Identifies Three Subgroups of Î²-Thalassemia with Distinct Clinical Severity. <i>Thalassemia Reports</i> , 2022, 12, 14-23.	0.5	3
161	Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2020, 30, 1048-1053.	1.0	2
162	Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C. <i>Minerva Gastroenterology</i> , 2021, 67, 254-263.	0.5	2

#	ARTICLE	IF	CITATIONS
163	Hepatitis C virus replication in chronic liver disease. <i>Journal of Hepatology</i> , 1991, 13, S40-S41.	3.7	1
164	A patient with acute hepatitis C and possible IFN toxicity. <i>Digestive and Liver Disease</i> , 2003, 35, 372-373.	0.9	1
165	Chronic hepatitis B: Do we know everything or is there still something to learn?. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 61-66.	0.2	1
166	Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. <i>Liver International</i> , 2020, 40, 530-538.	3.9	1
167	Adult to Adult Living Donor Liver Transplantation in Recipients with Low MELD: A Strategy Intended to Overcome Donor Shortage. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3477-3480.	2.3	1
168	Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study. <i>Digestive and Liver Disease</i> , 2022, 54, 1117-1121.	0.9	1
169	Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals. <i>Diagnostics</i> , 2022, 12, 1187.	2.6	0